Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

336

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Alogliptin and pioglitazone

Alogliptin 12.5 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.

DRUG

Alogliptin and pioglitazone

Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY